Pharmacometabolomics in Early-Phase Clinical Development

Clinical and Translational Science

Volumn 9, Issue 3, 2016, Pages 128-138

  Burt, T ^a   Nandal, S ^b  

^a Burt Consultancy   (United States)

^b Department of Medical Oncology Novartis ^*  (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CAPECITABINE; CITALOPRAM; ESCITALOPRAM; FLUOROURACIL; PARACETAMOL; SERTRALINE; SIMVASTATIN; TACROLIMUS;

CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; DRUG ANALYSIS; DRUG DESIGN; ENDOCRINOLOGY; GASTROENTEROLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACOMETABOLOMICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SAFETY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84975089443     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12396     Document Type: Review

References (54)

1. van der Greef, J., Hankemeier, T. & McBurney, R.N. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 7, 1087–1094 (2006).
2. Wilson, I.D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc. Natl. Acad. Sci. USA 106, 14187–14188 (2009).
3. Kaddurah-Daouk, R., Kristal, B.S. & Weinshilboum, R.M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48, 653–683 (2008).
4. Clayton, T.A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073–1077 (2006).
5. van der Greef, J. & Smilde, A.K. Symbiosis of chemometrics and metabolomics: past, present, and future. J. Chemometrics 19, 376–386 (2005).
6. Burt, T. & Dhillon, S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics 14, 1085–1097 (2013).
7. Kaddurah-Daouk, R., Weinshilboum, R.M. & Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin. Pharmacol. Ther. 95, 154–167 (2014).
8. Nicholson, J.K., Lindon, J.C. & Holmes, E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181–1189 (1999).
9. Winnike, J.H., Li, Z., Wright, F.A., Macdonald, J.M., O'Connell, T.M. & Watkins, P.B. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88, 45–51 (2010).
10. Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R. & Nicholson, J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA 106, 14728–14733 (2009).
11. Nicholson, J.K., Everett, J.R. & Lindon, J.C. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. Expert Opin. Drug Metab. Toxicol. 8, 135–139 (2012).
12. Robertson, D.G. & Frevert, U. Metabolomics in drug discovery and development. Clin. Pharmacol. Ther. 94, 559–561 (2013).
13. Lindon, J.C., Holmes, E. & Nicholson, J.K. Metabonomics techniques and applications to pharmaceutical research & development. Pharm. Res. 23, 1075–1088 (2006).
14. Gates, S.C. & Sweeley, C.C. Quantitative metabolic profiling based on gas chromatography. Clin. Chem. 24, 1663–1673 (1978).
15. Horning, M.G., Knox, K.L., Dalgliesh, C.E. & Horning, E.C. Gas-liquid chromatographic study and estimation of several urinary aromatic acids. Anal. Biochem. 17, 244–257 (1966).
16. Ryhage, R. & Stenhagen, E. Mass spectrometry in lipid research. J. Lipid Res. 1, 361–390 (1960).
17. Ward, M.E., Politzer, I.R., Laseter, J.L. & Alam, S.Q. Gas chromatographic mass spectrometric evaluation of free organic acids in human saliva. Biomed. Mass Spectrom. 3, 77–80 (1976).
18. Thompson, J.A. & Markey, S.P. Quantitative metabolic profiling of urinary organic acids by gas chromatography-mass spectrometry: comparison of isolation methods. Anal. Chem. 47, 1313–1321 (1975).
19. Thompson, J.A., Miles, B.S. & Fennessey, P.V. Urinary organic acids quantitated by age groups in a healthy pediatric population. Clin. Chem. 23, 1734–1738 (1977).
20. Games, D.E. et al. Analysis of pepper and capsicum oleoresins by high-performance liquid chromatography—mass spectrometry and field desorption mass spectrometry. J. Chromatography A 294, 269–279 (1984).
21. van der Greef, J., Tas, A.C., Bouwman, J., Ten Noever de Brauw, M.C. & Schreurs, W.H.P. Evaluation of field-desorption and fast atom-bombardment mass spectrometric profiles by pattern recognition techniques. Anal. Chim. Acta 150, 45–52 (1983).
22. Bain, J.R., Stevens, R.D., Wenner, B.R., Ilkayeva, O., Muoio, D.M. & Newgard, C.B. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 58, 2429–2443 (2009).
23. Oliver, S.G., Winson, M.K., Kell, D.B. & Baganz, F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 16, 373–378 (1998).
24. Fiehn, O. Metabolomics–the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155–171 (2002).
25. Kell, D.B., Brown, M., Davey, H.M., Dunn, W.B., Spasic, I. & Oliver, S.G. Metabolic footprinting and systems biology: the medium is the message. Nat. Rev. Microbiol. 3, 557–565 (2005).
26. James, L.P. Metabolomics: integration of a new “omics” with clinical pharmacology. Clin. Pharmacol. Ther. 94, 547–551 (2013).
27. Schnackenberg, L.K. & Beger, R.D. Metabolomic biomarkers: their role in the critical path. Drug Discov. Today Technol. 4, 13–16 (2007).
28. Institute of Medicine (IOM). Evolution of Translational Omics: Lessons Learned and the Path Forward. (The National Academies Press, 2012).
29. NIMH. From discovery to cure: accelerating the development of new and personalized interventions for mental illnesses. (The National Advisory Mental Health Council's Workgroup, 2010).
30. Woodcock, J. Continuing America's Leadership: The Future of Medical Innovation for Patients. Testimony before the Committee on Health, Education, Labor and Pensions, United States Senate. (US Food and Drug Administration, Washington, D.C., 2015).
31. Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293–1307 (2012).
32. Everett, J.R., Loo, R.L. & Pullen, F.S. Pharmacometabonomics and personalized medicine. Ann Clin Biochem 50(Pt 6), 523–545 (2013).
33. Urbanczyk-Wochniak, E. et al. Parallel analysis of transcript and metabolic profiles: a new approach in systems biology. EMBO Rep. 4, 989–993 (2003).
34. Kwon, H.N. et al. Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach. Kidney Int. 79, 529–537 (2011).
35. Yerges-Armstrong, L.M. et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 94, 525–532 (2013).
36. Phapale, P.B. et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin. Pharmacol. Ther. 87, 426–436 (2010).
37. Kaddurah-Daouk, R. et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6, 191–201 (2010).
38. Kaddurah-Daouk, R. et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 1, e26 (2011).
39. Backshall, A., Sharma, R., Clarke, S.J. & Keun, H.C. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin. Cancer Res. 17, 3019–3028 (2011).
40. Stebbing, J. et al. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann. Oncol. 23, 860–866 (2012).
41. Trupp, M. et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One 7, e38386 (2012).
42. Zhu, H. et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder – possible role for methoxyindole pathway. PLoS One 8, e68283 (2013).
43. Wikoff, W.R. et al. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One 8, e57639 (2013).
44. Ellero-Simatos, S. et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst. Pharmacol. 3, e125 (2014).
45. Ji, Y. et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 89, 97–104 (2011).
46. Collins, F.S. Mining for therapeutic gold. Nat. Rev. Drug Discov. 10, 397 (2011).
47. Paul, S.M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).
48. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).
49. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov. Today 17, 419–424 (2012).
50. Lenz, E.M. et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal. 36, 841–849 (2004).
51. Stella, C. et al. Susceptibility of human metabolic phenotypes to dietary modulation. J. Proteome Res. 5, 2780–2788 (2006).
52. Bai, J.P. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Drug Metab. Pharmacokinet. 25, 62–71 (2010).
53. McShane, L.M. et al. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med. 11, 220 (2013).
54. Kaddurah-Daouk, R. et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 3, e223 (2013).